Atea Pharmaceuticals, Inc.
AVIR · XNASCIK 1593899fmd_1CQAKQDSGFDXMG5ZRNB90JE7JNManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2018 to Sep 30, 2026, 32 periods
| Line item | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | 49 | 351 | – | – | – | – |
| Research and development | 7 | 10 | 38 | 167 | 82 | 114 | 144 | 148 |
| Total operating expenses | 9 | 15 | 60 | 213 | 131 | 164 | 193 | 181 |
| Operating income | (9) | (15) | (11) | 138 | (131) | (164) | (193) | (181) |
| Interest and investment income | 0 | 1 | 0 | 0 | 11 | 29 | 25 | 16 |
| Income before taxes | – | (14) | (11) | 139 | (119) | (135) | (167) | (165) |
| Income tax expense | – | – | – | 17 | (4) | 1 | 1 | (6) |
| Net income from continuing operations | – | – | – | 121 | (116) | (136) | (168) | (158) |
| Net income | (9) | (14) | (11) | 121 | (116) | (136) | (168) | (158) |